MM09 Mannosylated 5.000 sublingual
Phase 3Biologic
MM09 Mannosylated 5.000 sublingual is one of 69 biologic programs targeting Conjunctivitis. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
66 competitors in Allergic Asthma
#DrugCompanyPhaseTrials
1Xolair
RochePhase 3
Ventolin
AstraZenecaApproved
Xolair
RochePhase 3
Levocetirizine Dihydrochloride
UCBPhase 3
Symbicort
AstraZenecaPhase 3
Tezspire
AstraZenecaPhase 2
Daliresp
AstraZenecaPhase 2
Soliris
AstraZenecaPhase 2
EBGLYSS
Eli LillyPhase 2
Inhaled Corticosteroids
Boehringer IngelheimApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- IInmunotek S.L.